Biopharma happenings, including deals and partnerships, and other news in brief: Fractyl Health, Harrow, Melt, N4, Ocuvex, Onconetix, OSE, Sanofi, SRI, Theratechnologies.
In August 2025, BioWorld logged 95 clinical trial updates across phases I to III, compared to 140 tracked in July and 254 in June. Among them, 15 phase III studies delivered positive results, while one trial each reported a failure and mixed outcome.
Anaphylaxis rates caused Larimar Therapeutics Inc.’s stock (NASDAQ:LRMR) to take a hit on the latest data from an open-label study with nomlabofusp in the neuromuscular disease Friedreich’s ataxia (FA), but the company is targeting a BLA submission to seek accelerated approval in the second quarter of next year.
Enanta Pharmaceuticals Inc.’s phase IIb study of zelicapavir missed its primary endpoint in treating respiratory syncytial virus (RSV) but mined enough positive results to get the company to talk about advancing the once-daily oral treatment into further, larger studies.
Bar what it described as a “placebo wobble,” Moonlake Therapeutics AG turned in positive results from the phase III trials of sonelokimab in treating hidradenitis suppurativa (HS), only to see its share price take a complete battering. The stock (Nasdaq:MLTX) fell 90%, or $55.75, to close Sept. 29 at $6.24, after the Zug Switzerland-based company published 16-week data from two identical trials, Vela-1 and Vela-2.
RSS
